94% of patients suing Merck over rofecoxib agree to company's offer.
作者信息
Charatan Fred
出版信息
BMJ. 2008 Mar 15;336(7644):580-1. doi: 10.1136/bmj.39513.541296.DB.
Abstract
摘要
相似文献
1
94% of patients suing Merck over rofecoxib agree to company's offer.
BMJ. 2008 Mar 15;336(7644):580-1. doi: 10.1136/bmj.39513.541296.DB.
2
Court awards claimant 13.5m dollars in rofecoxib lawsuit.
BMJ. 2006 Apr 22;332(7547):927. doi: 10.1136/bmj.332.7547.927-a.
3
US judge dismisses 50m dollars damages in Vioxx lawsuit.
BMJ. 2006 Sep 9;333(7567):516. doi: 10.1136/bmj.333.7567.516-c.
4
Merck cleared in personal injury case against Vioxx.
BMJ. 2005 Nov 12;331(7525):1101. doi: 10.1136/bmj.331.7525.1101-a.
5
Quebec allows Vioxx class-action suit.
CMAJ. 2007 Jan 2;176(1):20. doi: 10.1503/cmaj.061600.
6
A message from the Vioxx case.
Am J Health Syst Pharm. 2006 Mar 15;63(6):503. doi: 10.2146/ajhp050427.
7
Merck to pay $5bn in rofecoxib claims.
BMJ. 2007 Nov 17;335(7628):1011. doi: 10.1136/bmj.39398.517176.DB.
8
[Rofecoxib increases myocardial infarction risk in seniors].
Med Monatsschr Pharm. 2005 Nov;28(11):416-7.
9
Merck VIOXX "warning" is questioned.
Tex Med. 2005 May;101(5):5-6.
10
NEJM editor gives pretrial evidence in Vioxx case.
BMJ. 2006 Feb 4;332(7536):255. doi: 10.1136/bmj.332.7536.255-a.
Zotero 插件